Subscribe to Niftyviews.com by email Add Team StockResearchers Headlines to your reader Share TSR with your friends SocialTwist Tell-a-Friend

24*7 CHAT ROOM

24*7 CHAT ROOM : TO LOGIN ENTER A USERNAME AND CLICK ON PROFILE.

ACTIVE CALLS- CALLS GIVEN BY TSR MODS IN CHAT ROOM

TO ENTER THE LIVE MARKET CHAT ENTER A USERNAME AND CLICK ON PROFILE.WISH TO JOIN OUR SERVICES.SIMPLY CLICK HERE FOR THE PROCEDURE.

GOOGLE SEARCH

ADS BY GOOGLE

Thursday, June 30, 2011

[T.S.R:17572] Positive view on upstream and pure refiners

Finally, some much needed relief !

The Government of India finally provided the much needed respite to the oil sector by way of price hikes of regulated products & duty relief on both crude and petro products. The Govt. has increased the retail prices of diesel by Rs.3/lit, LPG by Rs.50/cyl and kerosene by Rs.2/lit. Going further, the Govt. has also reduced excise duty on Diesel by Rs.2.6/lit and has also abolished customs duty on crude imports while reducing customs duty on petro products by 5%.

 

Valuation

Our SOTP valuation for ONGC yields a target price of Rs.338. Our price target translates into EV/boe of $5.9/boe and FY12E & FY13E P/E of 11x and 10.6x respectively. We have conservatively assumed the upstream sector to share 39% of gross under recoveries and excise duty on diesel to be restored to Rs.4.6/lit in FY13. The upcoming FPO may result in downward pressure on the stock price as there have been precedents of PSU FPOs being issued at a discount to the CMP to achieve maximum subscription. At our target price of Rs.338, the potential upside is 23.4% and we upgrade our rating on the stock to BUY and recommend subscribing to the FPO.

 

We value OIL India using DCF valuation with WACC of 12% and terminal growth rate of 2%. We maintain our BUY rating and raise our target price to Rs.1,512. Our price target translates into EV/boe of $6.1/boe and FY12E & FY13E P/E of 10.1x and 10.5x respectively.

 

We value MRPL using EV/EBITDA multiple of 6.25x on FY13E EBITDA and arrive at our price target of Rs.107, which translates to a hefty upside of 38.1%. MRPL is our top pick to play the strong refining cycle

 

We value Essar Oil by using SOTP valuation. We value the refinery using 6.25x FY13E EV/EBITDA and the Mehsana and Raniganj blocks using DCF. We value the Ratna/R-series & Nigerian blocks using EV/boe multiple. We upgrade our rating on the stock to BUY with a target price of Rs.168, which translates into an upside of 34.9%.

 

Please find attached file containing our view on - Oil Sector

 

LKP Research

10th Floor, Nariman Bhavan, Vinay K Shah Marg, Nariman Point, Mumbai – 400 021

Email: research@lkpsec.com, Web: www.lkpsec.com

 

 

The information in this documents has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true and is for general guidance only. While every effort is made to ensure the accuracy and completeness of information contained, the company makes no guarantee and assumes no liability for any errors or omissions of the information. No one can use the information as the basis for any claim, demand or cause of action.

LKP Securities Ltd., and affiliates, including the analyst who have issued this report, may, on the date of this report, and from time to time, have long or short positions in, and buy or sell the securities of the companies mentioned herein or engage in any other transaction involving such securities and earn brokerage or compensation or act as advisor or have other potential conflict of interest with respect to company/ies mentioned herein or inconsistent with any recommendation and related information and opinions. LKP Securities Ltd., and affiliates may seek to provide or have engaged in providing corporate finance, investment banking or other advisory services in a merger or specific transaction to the companies referred to in this report, as on the date of this report or in the past.

We are sorry if this mail has caused any distraction. If you want to be removed from the mailing list then you must reply to this mail with "Remove" in the subject line and e-mail for faster response and action



--
For Anything related with Stock market be Online at
http://www.niftyviews.com/
 
Get free updates on your mobile phone. Sms "Join TSR " and send to 09223492234
 
FOR TRIAL STOCK/NIFTY/OPTION CALLS
 
 
You received this message because you are subscribed to Google Group "STOCKRESEARCHER" group.
To post to this group, send an email to STOCKRESEARCHER@googlegroups.com
 
To unsubscribe email
Stockresearcher-unsubscribe@googlegroups.com
 
for more info visit
http://groups.google.com/group/STOCKRESEARCHER?hl=en-GB
.
This is Not a Spam Mail.
Disclaimer :-
"The opinions expressed by the members on this board are based on
their individual experience and perceptions and to share information
with other members with the best of intentions to help fellow members
in investment decisions as equity investment is a risky venture."

[T.S.R:17571] Andrew Wenk-GM Petroleum At Cairn India takes over as CEO Selan Oil Exploration

FYI

--
For Anything related with Stock market be Online at
http://www.niftyviews.com/
 
Get free updates on your mobile phone. Sms "Join TSR " and send to 09223492234
 
FOR TRIAL STOCK/NIFTY/OPTION CALLS
 
 
You received this message because you are subscribed to Google Group "STOCKRESEARCHER" group.
To post to this group, send an email to STOCKRESEARCHER@googlegroups.com
 
To unsubscribe email
Stockresearcher-unsubscribe@googlegroups.com
 
for more info visit
http://groups.google.com/group/STOCKRESEARCHER?hl=en-GB
.
This is Not a Spam Mail.
Disclaimer :-
"The opinions expressed by the members on this board are based on
their individual experience and perceptions and to share information
with other members with the best of intentions to help fellow members
in investment decisions as equity investment is a risky venture."

[T.S.R:17569] PERFORMANCE OF 29.06.2011'S TRADING CALL@TEAM STOCKRESEARCHERS @ www.niftyviews.com / http://smscalls.blogspot.com/

PERFORMANCE OF 29.06.2011'S TRADING CALL@TEAM STOCKRESEARCHERS @ www.niftyviews.com / http://smscalls.blogspot.com/


INTRADAY FUTURES +2000 PROFIT PER 1 Lot of Trading.Charges 7000 for 2 months.
TSR NIFTY ( +32) POINTS IN JUST 1 LOT.Charges 4000 for 2 months
INTRADAY OPTIONS = +0/1LOT.Charges 4500 for 2 month
s.

Here are the trading calls given by Team Stock researchers to its premium clients today.Its intra/futs/nifty futs /options service.Calls are sent by both sms and yahoo messenger.All are live calls.We dont give premarket calls.
Yahoo messenger id- NIFTYVIEWSCOM
Google talk support id- Contact@niftyviews.com

for payment details OR any further query email to contact@niftyviews.com

CASH CALLS
1calls given ,1 tgt done, 0 SL taken , 0 exited at cost
B uy Drreddy 1550 stoploss 1522 target 1580-1600 + We may hold it for 2 days.
Book partial profit in Drreddy future and cash and hold rest with sl at 1550. now at 1565. One lot holder hold with trailing sl. :)


 
 

NIFTY CALLS:
Buy Nifty future one lot at 5584 stoploss 5568 target 5600-5612
Nifty future on target one. :)
TOTALPOINTS COVERED=-+32


OPTIONS CALLS:
no calls



TOTAL PROFIT = +0rs/TRADING OF 1 LOT


For a Free Trial

Sms "Join TSR " and send to 09223492234
To subscribe FOR FREE TRIAL

SMS 'ON SRESEARCHERS' to 09870807070.
or be online in our chat room in market hours
http://www.niftyviews.com/

FOR PAYMENT DETAILS VISIT

http://groups.google.com/group/STOCKRESEARCHER/web/payment-details
VISIT

http://WWW.SMSCALLS.BLOGSPOT.COM/


FOR LAST YOU YEARS PERFORMANCE SHEET
FOR PAYMENT DETAILS VISIT
http://groups.google.com/group/STOCKRESEARCHER/web/payment-details


DO READ THE DISCLAIMER ON THE BLOG.PLEASE SEE THE BLOG FOR OUR PAST PERFORMANCE.ALSO REMEMBER THAT PERFORMANCE SHOULD NOT BE TAKEN AS AN EXPECTATION,INDICATION OR ACTUAL FUTURE PERFORMANCE.

http://smscalls.blogspot.com/


REGARDS
HIREN,
MANAS,
MITUL,
SHALIN,
SUNIL


ADMINISTRATORS.
TEAM STOCKRESEARCHERS
For Anything Related with stock markets and our online Live chat room visit


VISIT


http://www.niftyviews .com/

--
For Anything related with Stock market be Online at
http://www.niftyviews.com/
 
Get free updates on your mobile phone. Sms "Join TSR " and send to 09223492234
 
FOR TRIAL STOCK/NIFTY/OPTION CALLS
 
 
You received this message because you are subscribed to Google Group "STOCKRESEARCHER" group.
To post to this group, send an email to STOCKRESEARCHER@googlegroups.com
 
To unsubscribe email
Stockresearcher-unsubscribe@googlegroups.com
 
for more info visit
http://groups.google.com/group/STOCKRESEARCHER?hl=en-GB
.
This is Not a Spam Mail.
Disclaimer :-
"The opinions expressed by the members on this board are based on
their individual experience and perceptions and to share information
with other members with the best of intentions to help fellow members
in investment decisions as equity investment is a risky venture."

[T.S.R:17568] [Team Stock Researchers Pvt. Ltd.] 6/30/2011 06:33:00 PM



--
Posted By Laloo Laal to Team Stock Researchers Pvt. Ltd. at 6/30/2011 06:33:00 PM

--
For Anything related with Stock market be Online at
http://www.niftyviews.com/
 
Get free updates on your mobile phone. Sms "Join TSR " and send to 09223492234
 
FOR TRIAL STOCK/NIFTY/OPTION CALLS
 
 
You received this message because you are subscribed to Google Group "STOCKRESEARCHER" group.
To post to this group, send an email to STOCKRESEARCHER@googlegroups.com
 
To unsubscribe email
Stockresearcher-unsubscribe@googlegroups.com
 
for more info visit
http://groups.google.com/group/STOCKRESEARCHER?hl=en-GB
.
This is Not a Spam Mail.
Disclaimer :-
"The opinions expressed by the members on this board are based on
their individual experience and perceptions and to share information
with other members with the best of intentions to help fellow members
in investment decisions as equity investment is a risky venture."

[T.S.R:17567] Wyeth Ltd-Optimism Prevails; Slew Of Drug Launches, Better Access To Medicence To Aid Growth


Wyeth-51% Subsidiary Of Pfizer May Quote At Rs 1200 in A Year 

2011 was the first full year of operations of Wyeth as a part of the Pfizer group, the world's largest biopharmaceutical company, replete with milestones in sales, marketing and manufacturing. Wyeth continues to dominate the market in oral contraceptives and hormone therapy. 

With a view to consolidate it's position and grow faster, Wyeth is launching new Branded Value Offerings (BVOs) in Women's Health and Anti-Infectives, two areas where it has rich experience and heritage brands.

Wyeth's success in vaccines is well known. During 2011 sales of Prevenar 13, the new generation pneumococcal conjugate vaccine, continue to be buoyant. The vaccine is the largest selling toddler vaccine in the country.

 

In 2010-2011, the total audited pharmaceutical market in India grew by 15.9% to reach USD 12.2 billion. The retail sector accounted for USD 10.4 billion and grew at 15.3%, while the hospital sector accounted for USD 1.1 billion and grew by 26.0%. (Source : IMS MAT March 2011). According to IMS, currently the Indian pharmaceutical market ranks 14

th globally in terms of value and 3rd in volume. (January – December 2010).

Volumes contributed 7.6%, while new products contributed 6.5% and price contributed 1.2% to the growth of 15.3% achieved by the Indian pharmaceutical market during 2010-2011 (Source: IMS-SSA MAT March 2011). 

Opportunities  

The pharmaceutical market in India looks poised to grow to USD 55 billion in the next ten years, according to a report from McKinsey. At this projection, the market will be comparable to several developed markets. Even more impressive will be its level of penetration. In terms of volume, India will be at the top, a close second only to the US market. 

Over the years, India's healthcare sector has seen growth of corporate hospitals, as well as the expansion of chemist outlets to small towns. The growth in purchasing power of Indian consumers is expected to contribute to 40% of the projected market growth. Improvements in medical infrastructure will account for 20% growth.  

Greater health insurance penetration will add 15% and India's changing epidemiological profile will account for 10% growth. 

As per news reports, India plans to increase its allocation for healthcare from 0.94% to 2-3% of GDP over the next five years. This is a very positive step towards enabling healthcare. This coupled with overall economic growth and changing demographics can result in improved affordability and greater access to medicines. 

The industry is taking steps to expand beyond metros and cities to smaller towns, but its efforts are constrained by inadequate investment in rural infrastructure and low insurance penetration. 

Financials-Annualised 2011 EPS Rs 55 

The Company's sales for the period under review were Rs

636 crores. Sales for the period April 2010 – March 2011 were Rs 494 crores (April 2009 – March 2010, ` 429 crores) which represents a growth of 15% on a twelve month basis. The Company continues to maintain its leadership position in Oral Contraceptives, Hormone Therapy, Folic Acid and Pneumococcal Vaccine markets. 

The Company continues to invest in all the key brands to increase sales and also takes initiatives to reduce cost with a view to improving profitability and thus increase stakeholder value. The Company proposes to expand its presence in its key therapies by launching new Branded Value Offerings. 

In the field of anti-infectives, the Company launched Warclav* (amoxicillin-clavulanate combination) to build on its long legacy in the amoxicillin market and to consolidate its position in this segment. In the macrolides segment, the Company launched VICON* (Azithromycin tablets). 

During the year, the Company launched Prevenar 13* which protects children against 13 types of disease causing

Streptococcus pneumonia bacteria. Prevenar 13* offers a broader coverage against Streptococcus pneumoniae serotypes than that offered by the standard Prevenar Vaccine (PCV 7). Prevenar 13* has been well received by pediatricians and has grown to become one of India's largest selling vaccines.  

It received the Marketing Excellence Award from the Organisation of Pharmaceutical Producers of India (OPPI) in 2010. Increasing consumer franchise, improving market presence, new packaging and new formulations with ingredients such as Aloe Vera were the focus for the Company's Consumer Health care brands, Anne French* and Anacin*. Anacin* was relaunched as a smaller strip, with a convenient consumer price-point. Anacin* Multi Pain was rolled out in all the major states. 

OUTLOOK 

A McKinsey report says the BRIC countries (Brazil, Russia, India and China), will lead growth in the coming decade. Furthermore, India is expected to continue its high growth curve and rank among the top 11 global pharmaceutical markets by 2015. 

India's ascending economy has brought about a transition in the healthcare sector. At one end of the scale, like most emerging economies, India is experiencing a spurt in lifestyle diseases. At the other end of the scale, the challenges of communicable diseases continue to weigh heavily on India.

With the changing disease profile in India, the pattern of demand for medicines is also shifting. A decade ago, anti-infective and gastrointestinal drugs and vitamins accounted for 50% of the domestic market. By next year, they are expected to account for just 36%, says a PricewaterhouseCoopers report.

Conversely, drugs for cardiovascular problems, disorders of the central nervous system and other chronic diseases will account for 64% of total sales, up from 50% in 2001. India thus needs to deal with the problems of infectious diseases in addition to addressing the rapid upsurge in chronic disease risk factors and deaths, especially in urban settings. 

India's healthcare sector, growing at 16% annually, is likely to touch USD 350 billion by 2023, an eight-fold increase from 2008, estimates consulting firm Technopak. According to Ernst & Young, healthcare spending could rise to contribute 6.1% of India's GDP in 2012 (currently at 4.8% of GDP) and employ around nine million people (from four million today).


 
Safe Harbor Statement:

Some forward looking statements on projections, estimates, expectations & outlook are included to enable a better comprehension of the Company prospects. Actual results may, however, differ materially from those stated on account of factors such as changes in government regulations, tax regimes, economic developments within India and the countries within which the Company conducts its business, exchange rate and interest rate movements, impact of competing products and their pricing, product demand and supply constraints.
 
Nothing in this article is, or should be construed as, investment advice.
 
 
 

 
 

--
For Anything related with Stock market be Online at
http://www.niftyviews.com/
 
Get free updates on your mobile phone. Sms "Join TSR " and send to 09223492234
 
FOR TRIAL STOCK/NIFTY/OPTION CALLS
 
 
You received this message because you are subscribed to Google Group "STOCKRESEARCHER" group.
To post to this group, send an email to STOCKRESEARCHER@googlegroups.com
 
To unsubscribe email
Stockresearcher-unsubscribe@googlegroups.com
 
for more info visit
http://groups.google.com/group/STOCKRESEARCHER?hl=en-GB
.
This is Not a Spam Mail.
Disclaimer :-
"The opinions expressed by the members on this board are based on
their individual experience and perceptions and to share information
with other members with the best of intentions to help fellow members
in investment decisions as equity investment is a risky venture."

Wednesday, June 29, 2011

[T.S.R:17566] Tata Steel-Buy Before The Re-Rating; H2 Pessimism Recedes (Nomura)

Risks to Chinese steel prices now skewed to upside

Despite recent bearish newsflow on Chinese steel market sentiment, we are optimistic on the outlook for Chinese steel prices. We believe tighter monetary policy has driven flat steel inventories down 15-20% since March, setting the stage for a return of pricing power in H2. We expect underlying Chinese steel demand to improve in H2 as both industrial production growth and auto production pick up from Q2 softness.

European/US steel prices may be bottoming

The spread of European steel prices over Chinese prices has now fallen below $100/t, significantly reducing the threat of imports and removing downward pressure on European prices. The broad recovery in underlying steel demand appears solidly entrenched. In addition, key raw material prices remain elevated, while scrap prices in both the US and Europe have risen c.5% in the past month, suggesting further support to steel prices.

Sector re-rating likely as H2 pessimism recedes

The ongoing resilience of steel prices should allay investor fears of an H2 2011 margin squeeze and earnings slowdown comparable with H2 2010. With inventories relatively low and continued positive momentum in key end markets, we expect the seasonal slowdown in Q3 to be less pronounced in Europe than in previous years. Modest upward momentum in European and US steel prices could serve as a catalyst for sentiment towards the sector and this could lead to a relatively rapid re-rating as investors begin to discount a more stable H2 and a recovery in 2012 and beyond. We believe the current soft patch of economic data will be shortlived and recent share price weakness provides an attractive entry point.

MT offers greatest upside; buy now for multi-year cyclical recovery

At 5.7x 2012 EBITDA, we believe ArcelorMittal (MT) in particular is undervalued in the context of a continued steel recovery (5.5x is a midcycle multiple). We expect MT's EBITDA to grow at a CAGR of 21% to 2013 and its current share price (down 20% since Feb) offers an attractive entry point ahead of its multi-year march towards normalised earnings.

The stock could be one of the biggest beneficiaries of a sector snapback, with c.40% upside in our price target of €32.

Upcoming Q3 guidance a potential catalyst for MT

The market appears to be pricing in a y/y decrease in like-for-like H2 EBITDA, which we consider highly pessimistic given H2 2010 was characterised by a significant de-stocking. We expect MT's Q3 guidance to be solid in light of a more moderate summer slowdown in volumes, the repricing of legacy auto contracts and continued Mining expansion. We believe the stock could re-rate in the coming month as pessimism towards Q3 guidance and the H2 outlook recedes ahead of Q2 results (27 July).

--
For Anything related with Stock market be Online at
http://www.niftyviews.com/
 
Get free updates on your mobile phone. Sms "Join TSR " and send to 09223492234
 
FOR TRIAL STOCK/NIFTY/OPTION CALLS
 
 
You received this message because you are subscribed to Google Group "STOCKRESEARCHER" group.
To post to this group, send an email to STOCKRESEARCHER@googlegroups.com
 
To unsubscribe email
Stockresearcher-unsubscribe@googlegroups.com
 
for more info visit
http://groups.google.com/group/STOCKRESEARCHER?hl=en-GB
.
This is Not a Spam Mail.
Disclaimer :-
"The opinions expressed by the members on this board are based on
their individual experience and perceptions and to share information
with other members with the best of intentions to help fellow members
in investment decisions as equity investment is a risky venture."

[T.S.R:17565] [Team Stock Researchers Pvt. Ltd.] 6/29/2011 06:35:00 PM

 
 
Nifty EOD Chart 29 June 2011
Powered by : http://www.niftyviews.com/

Download free Historical / EOD data from our database stored on server and use it to create your NSE, BSE, FUT charts for technical analysis, for free trial calls Stock Futures, Stock Spot, Nifty Futures, Stock Options, Nifty Options





--
Posted By Laloo Laal to Team Stock Researchers Pvt. Ltd. at 6/29/2011 06:35:00 PM

--
For Anything related with Stock market be Online at
http://www.niftyviews.com/
 
Get free updates on your mobile phone. Sms "Join TSR " and send to 09223492234
 
FOR TRIAL STOCK/NIFTY/OPTION CALLS
 
 
You received this message because you are subscribed to Google Group "STOCKRESEARCHER" group.
To post to this group, send an email to STOCKRESEARCHER@googlegroups.com
 
To unsubscribe email
Stockresearcher-unsubscribe@googlegroups.com
 
for more info visit
http://groups.google.com/group/STOCKRESEARCHER?hl=en-GB
.
This is Not a Spam Mail.
Disclaimer :-
"The opinions expressed by the members on this board are based on
their individual experience and perceptions and to share information
with other members with the best of intentions to help fellow members
in investment decisions as equity investment is a risky venture."

[T.S.R:17564] JB Chemicals-BUY

We have made some rough calculations for JB chemicals based on the conf call transcript on the website

The downside appears limited (PFA our working excel and an ENAM report on the company - plz ignore the russia part)

 

Comments/suggestions invited.....

 

 

A

Valuation - As per CMP downside appears limited

B

Calculation Of net debt

Particulars

 

Amt

Debt as on Mar 2010

Rs cr

136

Cash in books

Rs per share

102.4

3 yr avg operating cash flow for 2010-11

Rs cr

80

40% discount ('coz investing in pharma business)

 

40%

Cash as on mar 2010

Rs cr

78

After cash

Rs per share

61.42854208

Net debt

Rs cr

-22

Total Business Revenues before deal

Rs crs

800

Remaining business revenues

Rs crs

615

EV (assuming a price/sales multiple of 1)

Rs crs

615

Net Debt

Rs crs

-22

Equity Value

Rs crs

637

No of shares

Crs

8.45

Per share value (assuming a price/sales multiple of 1)

Rs per share

75

Total Value in case of non payment of dividend

Rs per share

137

CMP

Rs per share

128

C

Remaining Business revenues as per mgt in concall

D

Cash in books

ROW

m$

28

Cash recd

Rs cr

1160

Russia Prescription

m$

22

Escrow acccount (payable 15 months later)

15%

174

j&J

m$

20

Balance receivable after 1 month

Rs cr

986

 

m$

70

Discounting with 12%

 

977

Exchange rate

Rs/$

45

Discounting of escrow money with 12%

 

147

 

Rs cr

315

Present Value of total money receivable

 

1124

Domestic

Rs cr

300

Tax Rate

 

23%

Total

Rs cr

615

Final Balance

Rs cr

865

Per share cash

Rs

102.4

E

Some +ve developments

1

Ashish Dhawan holding ~7% and buying additional 5.6 lakh shares @128 Rs after deal

JB Chemicals & Pharmaceuticals Ltd.

Industry

: Pharmaceuticals & Drugs

House

: Private

Trade Price(Rs.)

Value (Rs.in Lakhs)

Exchange

Deal Date

Client Name

Tran

Qty (000's)

128.02

72388397

Close Price(Rs.)

NSE

25-May-11

ASHISH DHAWAN

BUY

565446

127.95

2

Sale of Russia business seems like good riddance as it was not returning funds anyways

Mar 2010 consolidated P&L sales roughly ~ Rs740 cr ...almost    half of which is stuck as sundry debtors of Rs 340 cr, out of which    almost half is debtors more than 6 months i.e. Rs 172 cr....

F

Possible setbacks

1

Management going back on their words like GeeCee Ventures/ Gwalior Chemicals. Went back on their word of investing in pharma, went back on giving dividend, announced buyback and went ahead with NBFC

Probability of the above event appears to be low

2

The presence of a savvy investor Like Ashish Dhawan need not ensure that minority share holders interest is taken care of, as was seen in the case of Indo asian fusegear where Ashish holds 8%

G

Links:

1

Conf call transcript

2

Money control Vidoes

 

 

Thanks & Regards

Sunil Pal

Sales Manager-PCG

CD Equisearch Pvt Ltd
517-519,5th Floor,Antariksh Bhawan
22 K.G.Marg,New Delhi-110001
Ph.No 011-45059486

Mob. +91 9899787890

Email-sunil.pal@cdequi.com




--
For Anything related with Stock market be Online at
http://www.niftyviews.com/
 
Get free updates on your mobile phone. Sms "Join TSR " and send to 09223492234
 
FOR TRIAL STOCK/NIFTY/OPTION CALLS
 
 
You received this message because you are subscribed to Google Group "STOCKRESEARCHER" group.
To post to this group, send an email to STOCKRESEARCHER@googlegroups.com
 
To unsubscribe email
Stockresearcher-unsubscribe@googlegroups.com
 
for more info visit
http://groups.google.com/group/STOCKRESEARCHER?hl=en-GB
.
This is Not a Spam Mail.
Disclaimer :-
"The opinions expressed by the members on this board are based on
their individual experience and perceptions and to share information
with other members with the best of intentions to help fellow members
in investment decisions as equity investment is a risky venture."

Google
 

Sign by Dealighted - Coupons and Deals